Candesartan for the treatment of hypertension and heart failure

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1589-1597

  Östergren, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin receptor antagonist; Candesartan; Clinical trials; Heart failure; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; SPIRONOLACTONE;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERABILITY; HEART FAILURE; HEART VENTRICLE FUNCTION; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLE;

ADMINISTRATION, ORAL; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EXPERT TESTIMONY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 3543069473     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1589     Document Type: Article

References (38)

1. STEWART S, MACINTYRE K, CAPEWELL S, MCMURRAY JJV: Heart failure and the aging population: an increasing burden in the 21st century? Heart (2003) 89(1):49-53.
2. GARG R, YUSUF S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA (1995) 273(18):1450-1456.
3. CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353(9146):9-13.
4. MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001-2007.
5. PACKER M, COATS AJS, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344(22):1651-1658.
6. PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. (1999) 341(10):709-717.
7. THE DIGITALIS INVESTINGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. (1997) 336(8):525-533.
8. RICH MW: Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J. Am. Ger. Soc. (1997) 45(8):968-974.
9. REDFIELD MM: Heart failure - An epidemic of uncertain proportions. N. Engl. J. Med. (2002) 347(18):1442-1444.
10. NISHIKAWA K, NAKA T, CHATANI F, YOSHIMURA Y: Candesartan cilexetil: A review of its preclinical pharmacology. J. Hum. Hypertens. (1997) 11(2 Suppl.):S9-S17.
11. OJIMA M, INADA Y, SHIBOUTA Y et al.: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. J. Pharmacol. (1997) 319(1):137-146.
12. EASTHOPE S E, JARVIS B: Candesartan cilexitil. An update of its use in essential hypertension. Drugs (2002) 62(8):1253-1287.
13. LACOURCIERE Y, ASMAR R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am. J. Hypertens. (1999) 12:1181-1187.
14. MANOLIS AJ, GROSSMAN E, JELAKOVIC B et al.: Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin. Ther. (2000) 22(10):1186-1203.
15. BAKRIS G, GRADMAN A, REIF M et al.: Antihypertensive efficacy of candesartan in comparison to losartan: the claim study. J. Clin. Hypertens. (Greenwich) (2001) 28;3(1):16-21.
16. VIDT DG, WHITE WB, RIDLEY E et al.: A forced titration study of antihypertensive efficacy of candesartan cilexitil in comparison to losartan: CLAIM Study I. J. Hum. Hypertens. (2001) 15(7):475-480.
17. CUSPIDI C, MUIESAN ML, VALAGUSSA L et al.: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens. (2002) 20(11):2293-2300.
18. MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. (2000) 321(7274):1440-1444.
19. ROSSING K, JACOBSEN P, PIETRASZEK L, PARVING HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care (2003) 26(8):2268-2274.
20. LITHELL H, HANSSON L, SKOOG I et al.: The study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J. Hypertens. (2003) 21(5):875-886.
21. LINDHOLM LH, PERSSON M, ALAUPOVIC et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. (2003) 21(8):1563-1574.
22. MCKELVIE R, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril and their combination in CHF. Randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation (1999) 100:1056-1064.
23. MCKELVIE RS, ROULEAU JL, WHITE M et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur. Heart J. (2003) 24(19):1727-1734.
24. GRANGER CB, ERTL G, KUCH J et al.: Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. (2000) 139(4):609-617.
25. RIEGGER GAJ, BOUZO H, PETR P et al.: for the Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation (1999) 100:2224-2230.
26. PFEFFER M, SWEDBERG K, GRANGER C et al.: for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet (2003) 362:759-766.
27. GRANGER C, MCMURRAY J, YUSUF S et al., for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet (2003) 362:767-771.
28. MCMURRAY J, ÖSTERGREN J, SWEDBERG K et al., for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet (2003) 362:772-776.
29. YUSUF S, PFEFFER M, SWEDBERG K et al., for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan in patients with chronic heart failure and left ventricular ejection fraction above 40%: the CHARM-Preserved Trial. Lancet (2003) 362:777-7816.
30. MCMURRAY J, ÖSTERGREN J, PFEFFER M et al., on behalf of the CHARM COMMITTEES AND INVESTIGATORS: Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Programme. Eur. J. Heart Failure (2003) 5:261-270.
31. THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. (1991) 325(5):293-302.
32. COHN J, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in CHF. N. Engl. J. Med. (2001) 345(23):1667-1675.
33. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345(12):851-860.
34. BRENNER BM, COOPER ME, DE ZEELTW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345(12):861-869.
35. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995-1003.
36. PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355(9215):1582-1587.
37. YUSUF S, GERSTEIN H, HOOGWERF B et al.: Ramipril and the development of diabetes. JAMA (2001) 286(15):1882-1885.
38. ALLHAT OFFICERS AND COORDINATORS, for the ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2000) 288(23):2981-2997.